On June 6, 2016 Amyris, an industrial bioscience company, entered into a research agreement with a commercial license option, with Janssen Biotech, a subsidiary of Janssen Pharmaceutical Companies. Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, the collaboratiOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.